Poland Freezes Drug Prices For Rest Of Year
Poland's Finance Minister, Grezegorz Kolodko, has said that the latest rise in drug and medicine prices will be the last in 1995. The 1995 budget originally envisaged drug price rises of about 2% in second-half 1995, but Mr Kolodko has decided this will not be introduced. Prices of Polish-made drugs covered by official prices and reimbursed from the state budget have just been raised 14%.
Eastern European News Reports In Brief - Health care costs in the Czech Republic rose 0.1% in April over March, reports the CTK news agency's Business News. April's general inflation rate was 0.4%.
Meantime, Czech Health Minister Ludek Rubas has told the republic's social affairs and health committee that the problems faced by the national health service are due to a rapid defection of health care workers to the private sector. 14,000 employees, including 4,500 doctors and over 600 nurses, have left the service.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze